Fulcrum Therapeutics scrapped its sole clinical-stage sickle cell ambitions and will seek an exit after FDA feedback tied to safety concerns referenced a recently withdrawn cancer drug from Ipsen. The company’s decision reflects the regulatory sensitivity around modality and safety signals as the FDA considers class-relevant risk. Fulcrum had planned to enter a registrational trial, but the regulatory response triggered a strategic halt rather than redesign and continuation. The regulatory feedback links patient risk assessment to broader oversight patterns beyond the company’s specific program. For other developers, the action serves as a reminder that modality-level safety concerns can cascade quickly into program termination decisions. The next steps for Fulcrum center on exit planning and communications to stakeholders as timelines tied to development and value creation reset.